Cargando…

Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects

Quetiapine is an established drug for treatment of schizophrenia, bipolar disorder, and major depressive disorder. While initially manufactured as an immediate-release (IR) formulation, an extended-release (XR) formulation has recently been introduced. Pharmacokinetic studies show that quetiapine XR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nord, Magdalena, Nyberg, Svante, Brogren, Jacob, Jucaite, Aurelija, Halldin, Christer, Farde, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198174/ https://www.ncbi.nlm.nih.gov/pubmed/21477416 http://dx.doi.org/10.1017/S1461145711000514

Ejemplares similares

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili, Nizar
Publicado: (2012)

GABA(A) receptor occupancy by subtype selective GABA(Aα2,3) modulators: PET studies in humans
por: Jucaite, Aurelija, et al.
Publicado: (2016)

PET imaging of [(11)C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
por: Varnäs, Katarina, et al.
Publicado: (2018)

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott, Jean, et al.
Publicado: (2012)

Role of extended release quetiapine in the management of bipolar disorders
por: Al Jurdi, Rayan K, et al.
Publicado: (2010)

Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults
por: Swearingen, Dennis, et al.
Publicado: (2018)

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
por: Ena, Javier, et al.
Publicado: (2012)

Kinetic analysis and test-retest variability of the radioligand [(11)C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
por: Jučaite, Aurelija, et al.
Publicado: (2012)

Formulation Design and Optimization of Orodispersible Tablets of Quetiapine Fumarate by Sublimation Method
por: Kalyankar, P., et al.
Publicado: (2015)

Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia
por: Akhlaq, Muhammad, et al.
Publicado: (2018)

Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane
por: Bhupathyraaj, Mullaicharam, et al.
Publicado: (2022)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014)

Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders
por: Hallinen, Taru, et al.
Publicado: (2012)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy
por: Rinne, Juha O., et al.
Publicado: (2022)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Rhabdomyolysis following Acute Extended-Release Quetiapine Poisoning: A Case Report
por: Liolios, Antonios, et al.
Publicado: (2012)

Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
por: Murasaki, Mitsukuni, et al.
Publicado: (2018)

Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
por: Oggianu, Laura, et al.
Publicado: (2022)

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union
por: Brody, Robert S., et al.
Publicado: (2018)

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations
por: Fontova, Pere, et al.
Publicado: (2023)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
por: Stenkrona, Per, et al.
Publicado: (2019)

Insights into the Control of Drug Release from Complex Immediate Release Formulations
por: Dong, Runqiao, et al.
Publicado: (2021)

Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries
por: Sumarsono, Andrew, et al.
Publicado: (2020)

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
por: Lundberg, Johan, et al.
Publicado: (2012)

Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder
por: McIntyre, Roger S., et al.
Publicado: (2015)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Branch retinal vein occlusion associated with quetiapine fumarate
por: Yong, Ku Chui, et al.
Publicado: (2011)

Quetiapine N-oxide–fumaric acid (2/1)
por: Shen, Jin, et al.
Publicado: (2012)

Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME)
por: Karamustafalıoğlu, Oğuz, et al.
Publicado: (2014)

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
por: Kanba, Shigenobu, et al.
Publicado: (2019)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics
por: Sangoi, Maximiliano S., et al.
Publicado: (2015)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach
por: Mukherjee, Arnab, et al.
Publicado: (2022)

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
por: Vaidya, Varun, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bui6kjlaefjaevcqoo2beibssk